Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates

Core Insights - Fulgent Genetics, Inc. (FLGT) reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of$0.12 per share, representing an earnings surprise of 133.33% [1] - The company achieved revenues of $76.21 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.90$70.51 million year-over-year [2] - Fulgent Genetics has outperformed consensus EPS estimates in four consecutive quarters and has topped consensus revenue estimates three times in the last four quarters [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of$74.8 million, and for the current fiscal year, it is -$0.09 on revenues of$326.34 million [7] Industry Context - The Medical Info Systems industry, to which Fulgent Genetics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, TruBridge (TBRG), is expected to report quarterly earnings of $0.58 per share, reflecting a year-over-year increase of 61.1% [9]